Siloam International Hospitals (SILO) Stock 2027: Financial Outlook, Valuation and Investment Thesis
Published: October 30, 2025
Last Updated: October 7, 2026
Financial data and analysis reviewed as of October 7, 2026.
 |
| Siloam International Hospitals (SILO) |
Worldreview1989 - Siloam International Hospitals Tbk (IDX: SILO) is increasingly interesting for investors looking beyond Indonesia's traditional banking, commodity, and technology sectors. As Indonesia's healthcare system continues to expand, Siloam offers exposure to a structural theme that is easier for international investors to understand: rising healthcare utilization, expanding insurance coverage, higher medical complexity, and increasing demand for quality hospital services.
For an American investor, however, SILO should not be viewed simply as an Indonesian version of a U.S. hospital operator. The economics are different. Indonesia's healthcare financing system, JKN national insurance program, patient mix, reimbursement mechanisms, operating costs, and capital-market valuation all create a different risk-return profile.
The more important question for 2027 is therefore not simply whether Siloam can grow revenue.
The key question is whether Siloam can convert Indonesia's expanding healthcare demand into sustainable earnings growth without sacrificing margins or capital efficiency.
Check : Indonesia Stock Exchange Listed Companies Directory
Siloam International Hospitals at a Glance
Siloam International Hospitals is listed on the Indonesia Stock Exchange under the ticker SILO. KSEI records 13.006 billion shares outstanding, with the company classified in the healthcare sector.
The company operates in a market with significant structural demand.
Indonesia's healthcare expenditure reached approximately Rp639.9 trillion in 2024, equivalent to 2.9% of GDP, according to the World Health Organization's Indonesia Health Accounts. WHO also reported that healthcare spending has nearly doubled over the past decade, with utilization of Indonesia's national health insurance system playing a major role.
This matters for SILO because hospital demand is not purely discretionary. Medical treatment, surgery, diagnostics, emergency care, specialist services, and chronic disease management can create recurring demand even when economic growth slows.
2025 Financial Performance: The Starting Point for 2027
Siloam entered the 2027 investment discussion from a considerably stronger financial position than it had several years ago.
For FY2025, SILO reported:
| Financial Metric | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Revenue | Rp12.21T | Rp12.85T | +5.2% |
| EBITDA | — | Rp2.83T | Strong growth |
| Net Profit | Rp902.2B | Rp1.11T | +23.3% |
| EBITDA Margin | — | ~22.0% | Improving |
| Net Margin | — | ~8.7% | Improving |
The FY2025 numbers show an important characteristic of the SILO investment thesis: profitability grew considerably faster than revenue.
Revenue increased 5.2%, while net profit increased approximately 23%. This indicates operating leverage and/or better profitability mix rather than simple top-line expansion.
For a long-term investor, this is more important than headline revenue growth.
A healthcare company that grows revenue 10% but cannot expand margins may create limited shareholder value. Conversely, a company growing revenue moderately while expanding EBITDA and net margins can potentially generate much faster EPS growth.
2026 Is Providing an Important Confirmation
The first half of 2026 strengthens the investment case.
Siloam generated approximately Rp6.76 trillion of revenue during the first six months of 2026, compared with Rp6.10 trillion in the same period of 2025.
Reported EBITDA reached approximately Rp1.34 trillion, while attributable net income was around Rp580.7 billion, according to the H1 2026 financial data.
The reported figures indicate:
Revenue growth: approximately 10.8%
EBITDA growth: approximately 5.1%
Attributable net profit growth: approximately 27%
EPS: approximately Rp44.7 for H1 2026
The acceleration in earnings is particularly interesting.
It suggests that SILO's earnings growth does not have to depend entirely on opening new hospitals. Improvements in utilization, service mix, pricing, specialist services, operational efficiency, and existing hospital productivity can potentially create earnings growth from the existing asset base.
That is an important distinction for investors.
The Most Important 2027 Question: Can SILO Maintain Earnings Growth?
A simple extrapolation of H1 2026 would put full-year 2026 attributable earnings in the neighborhood of Rp1.15–1.25 trillion, although the actual result will depend on second-half performance.
For 2027, I would use a scenario approach rather than a single aggressive forecast.
Base Case
Assumptions:
Revenue growth: 8–10%
EBITDA margin: approximately 20–22%
Net profit growth: 12–18%
No major deterioration in reimbursement economics
Continued improvement in hospital utilization
Under this scenario, 2027 attributable net income could potentially approach Rp1.4–1.5 trillion.
With approximately 13 billion shares outstanding, that would imply EPS in the neighborhood of:
Rp108–Rp115 per share.
This is not company guidance. It is a scenario-based analytical estimate.
Bull Case: SILO Becomes an Indonesian Healthcare Compounder
The bullish scenario assumes that several trends reinforce each other.
Hospital utilization continues rising.
Specialist and higher-value medical services grow faster than basic services.
Existing hospitals improve productivity.
New capacity reaches attractive utilization levels.
EBITDA margin remains around or above 22%.
Net income grows faster than revenue.
Healthcare expenditure continues expanding faster than the overall economy.
Under such conditions, 2027 earnings could potentially reach approximately Rp1.55–Rp1.70 trillion.
At 13 billion shares, that would correspond to EPS of roughly:
Rp119–Rp131 per share.
A healthcare company capable of sustaining double-digit EPS growth could deserve a premium valuation.
Bear Case: The Main Risk Is Not Demand
The bearish scenario is more complicated.
Healthcare demand itself is unlikely to disappear. The bigger concern is who pays, how much they pay, and how much margin the hospital retains.
Indonesia's JKN system has dramatically increased healthcare access. The World Bank reported that JKN had reached approximately 280 million members by July 2025, equivalent to about 98% of Indonesia's population. At the same time, the World Bank has highlighted the need for sustainable healthcare financing and cost controls because hospital expenditure has grown rapidly.
This creates a structural paradox for SILO:
More healthcare utilization is positive for hospital volumes, but higher utilization does not automatically mean higher profitability.
If reimbursement rates are constrained while labor, pharmaceuticals, equipment, utilities, and other operating costs rise, revenue growth could fail to translate into earnings growth.
In a bear case, 2027 net income might remain around Rp1.2–1.3 trillion, resulting in EPS closer to Rp92–Rp100.
2027 Valuation Framework
 |
| Siloam International Hospitals (SILO) |
At around Rp1,905 per share on October 6, 2026, SILO was trading substantially below its early-2026 levels. Historical market data shows SILO closing at Rp1,905 on October 6, 2026.
Using a hypothetical 2027 EPS range:
| Scenario | 2027 EPS Estimate | P/E Assumption | Implied Value |
|---|---|---|---|
| Bear | Rp92 | 16x | Rp1,472 |
| Conservative | Rp100 | 18x | Rp1,800 |
| Base | Rp112 | 20x | Rp2,240 |
| Bull | Rp125 | 22x | Rp2,750 |
| Strong Bull | Rp131 | 25x | Rp3,275 |
This table is a scenario valuation, not a price target issued by Siloam or a securities analyst.
The most interesting area is the base case.
If SILO can generate approximately Rp110–Rp115 EPS in 2027 and investors are willing to pay approximately 20x earnings, the theoretical valuation would fall around Rp2,200–Rp2,300.
That would provide meaningful upside from the October 2026 price level.
However, the market does not owe SILO a 20x multiple.
The multiple must be earned through sustained earnings growth, strong return on capital, balance-sheet discipline, and confidence in healthcare reimbursement economics.
Why American Investors May Find SILO Interesting
An American reader evaluating SILO would probably focus on several concepts familiar from U.S. healthcare investing.
1. Healthcare is a structural-growth industry
Healthcare demand tends to be more resilient than many cyclical industries.
Indonesia's large population and expanding middle class provide a substantial long-term addressable market.
The World Bank estimates Indonesia's 2025 population at approximately 285.7 million.
That scale gives successful healthcare operators an enormous potential market.
2. Insurance coverage can expand the addressable market
The growth of JKN has fundamentally changed Indonesia's healthcare economics.
As more people gain access to formal healthcare financing, previously delayed medical treatment can move into the formal healthcare system.
The World Bank reported that healthcare utilization increased from 378 million visits in 2020 to 686 million visits in 2024.
For a hospital operator, increasing utilization can create operating leverage when capacity is already available.
3. Indonesia is entering a more complex healthcare-demand phase
Indonesia is not simply becoming more populous.
It is also experiencing urbanization, changing lifestyles, and an epidemiological transition toward chronic diseases.
The World Bank specifically identifies aging populations, urbanization, and increasing non-communicable disease burdens as major forces reshaping healthcare demand across developing economies, including Indonesia.
That potentially increases demand for:
cardiovascular treatment
oncology
neurology
orthopedics
renal care
diagnostic imaging
specialist surgery
long-term chronic disease management
These services can have a different economic profile from basic outpatient care.
The Hidden Driver: Revenue Mix
One of the most important aspects of the SILO story is mix, not simply volume.
During H1 2026, non-specialist revenue was approximately Rp5.23 trillion while specialist revenue was approximately Rp1.53 trillion. Both segments increased compared with the prior year.
For investors, the strategic question is whether Siloam can progressively increase the contribution of higher-value services without creating excessive capital requirements.
This could become one of the biggest determinants of 2027–2030 EPS growth.
A hospital operator does not necessarily need to build dozens of new facilities to grow earnings rapidly.
It can also:
increase revenue per bed → improve utilization → increase specialist mix → improve asset productivity → expand margins → increase EPS.
That is potentially a much more capital-efficient growth model.
Balance Sheet: An Underappreciated Positive
SILO's balance sheet also deserves attention.
The H1 2026 financial statements show total assets of approximately Rp15.83 trillion, compared with approximately Rp14.50 trillion at the end of 2025. Cash and cash equivalents increased to approximately Rp1.23 trillion from Rp1.16 trillion.
The financial data also indicate relatively manageable debt compared with the company's EBITDA generation.
This gives SILO more flexibility than a highly leveraged hospital operator.
For investors, balance-sheet strength matters because hospital expansion is capital intensive.
A company with excessive debt can be forced to choose between:
expanding capacity,
maintaining facilities,
paying dividends,
or protecting liquidity.
A healthier balance sheet provides more strategic options.
What Could Go Wrong in 2027?
A serious investment article should not only explain the upside.
Reimbursement Risk
The expansion of JKN is positive for utilization, but government and insurance reimbursement policies can influence hospital profitability.
Cost-control reforms are an explicit part of Indonesia's healthcare strategy. The World Bank notes that Indonesia has been strengthening payment mechanisms, standardized care protocols and cost controls to improve sustainability.
This means investors should monitor reimbursement economics, not just patient volume.
Wage and Medical-Supply Inflation
Healthcare is labor intensive.
Doctors, nurses, technicians, specialists and administrative personnel are essential to the operating model.
At the same time, pharmaceuticals, medical equipment and imported technology can expose hospitals to cost inflation and currency movements.
If costs rise faster than pricing and productivity, margins can compress.
Capital Expenditure
Healthcare assets require continuous investment.
Hospitals need:
medical equipment
operating-room technology
imaging equipment
IT systems
building maintenance
hospital upgrades
specialist infrastructure
Therefore, EBITDA growth should not automatically be interpreted as free-cash-flow growth.
Investors should examine cash flow after capital expenditure, not EBITDA alone.
Valuation Risk
This may be the biggest stock-market risk.
SILO can be an excellent company and still be a poor investment if purchased at an excessive valuation.
Healthcare stocks often receive premium multiples because investors value their recurring demand and structural growth.
But premium multiples can contract quickly if earnings growth disappoints.
Therefore, investors should distinguish:
good company ≠ automatically cheap stock.
My 2027 Investment Thesis
 |
| Siloam International Hospitals (SILO) |
My analytical view is that SILO's 2027 story should be based on earnings quality rather than headline revenue growth.
The most attractive scenario is one in which:
Revenue growth 8–10%
Net profit growth 12–18%
Stable/improving EBITDA margin
Controlled leverage
Higher-value specialist services
=
Potential EPS compounding
This is the type of financial profile that can justify a premium valuation.
SILO Stock 2027: Bull, Base and Bear Outlook
🟢 Bull Case
Siloam successfully improves hospital utilization, expands specialist services, maintains margins and benefits from continued healthcare spending growth.
Potential 2027 EPS: Rp120–Rp130+
Potential valuation range: Rp2,600–Rp3,200+
Investment profile: High-quality growth healthcare stock
🟡 Base Case
Revenue continues growing at high single digits, earnings grow in the low-to-mid teens, and valuation remains around 18–21x forward earnings.
Potential 2027 EPS: approximately Rp105–Rp115
Potential valuation range: Rp1,900–Rp2,400
Investment profile: Reasonable long-term healthcare compounder
🔴 Bear Case
Reimbursement pressure, operating costs, slower utilization growth or valuation compression limit earnings growth.
Potential 2027 EPS: approximately Rp90–Rp100
Potential valuation range: Rp1,400–Rp1,800
Investment profile: Defensive demand, but weaker shareholder returns
What Should Investors Monitor Before Buying SILO?
For a 2027 investment thesis, I would monitor six indicators every quarter:
Revenue growth
EBITDA margin
Net profit growth
Revenue per bed / hospital utilization
Specialist-service contribution
Operating cash flow versus capital expenditure
The sixth metric is particularly important.
If SILO reports rising net profit but operating cash flow and free cash flow fail to follow, investors should investigate why.
Final Verdict: Is SILO Stock Attractive for 2027?
Siloam International Hospitals is one of the more interesting structural-growth healthcare stocks on the Indonesia Stock Exchange for a 2027 investment horizon.
The investment case is supported by several long-term factors:
Indonesia's large population
expanding healthcare utilization
very broad JKN coverage
rising healthcare expenditure
increasing demand for specialist services
improving profitability
relatively manageable leverage
potential operating leverage from existing hospital capacity
The strongest evidence is not simply the size of Indonesia's healthcare market.
It is the fact that Siloam's earnings have recently been growing faster than revenue.
That is the characteristic I would watch most closely going into 2027.
At the October 6, 2026 closing price of approximately Rp1,905, the stock deserves a closer valuation review rather than being dismissed purely because healthcare is a relatively defensive sector.
My base-case framework places reasonable 2027 value around Rp1,900–Rp2,400, with a bullish scenario extending toward Rp2,600–Rp3,200 if earnings growth and margins continue to outperform.
The critical caveat is that these are analytical scenario values, not guaranteed price targets.
For an American investor, the key takeaway is straightforward:
SILO is not primarily a bet on Indonesian hospital buildings. It is a bet on the monetization of Indonesia's long-term healthcare demand.
If Siloam can turn increasing patient utilization into higher-margin specialist revenue while maintaining capital discipline, the company could become a compelling healthcare compounder through 2027 and beyond.
If reimbursement pressure prevents that conversion, the stock's valuation premium could become its biggest weakness.
Investment stance: WATCHLIST / ACCUMULATE ON ATTRACTIVE VALUATION
The stock becomes more compelling when earnings growth remains in the double digits while the forward P/E moves toward a reasonable range relative to its growth and return on capital.
Primary & Authoritative Sources
PT Siloam International Hospitals Tbk is an Indonesian healthcare company engaged in the hospital and human healthcare services business. The company’s shares are listed on the Indonesia Stock Exchange (IDX) under the ticker symbol SILO. According to the company’s Annual Report, Siloam focuses on expanding access to quality healthcare services while developing its hospital network, medical capabilities, technology, and healthcare infrastructure.
Citation:
PT Siloam International Hospitals Tbk, Annual Report 2024, Company Profile and Corporate Information.
https://mysiloam-api.siloamhospitals.com/storage-down/file-web-cms/17459502701625876.pdf
Additional Primary Source:
PT Siloam International Hospitals Tbk, 2025 Annual Report, including company profile, management discussion and analysis, financial highlights, business development, and corporate governance information.
https://www.siloamhospitals.com/en/investor-relations
“According to PT Siloam International Hospitals Tbk’s Annual Report, the company operates in Indonesia’s healthcare sector and its shares are listed on the Indonesia Stock Exchange under the ticker symbol SILO.”
About the Author
Investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Alternative Assets
- Business & Startups
- Franchise
- Insurance
- Property and Real Estate
- Stocks
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks.